The 10 most recent market catalysts affecting $HAE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 65
Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123
Citigroup analyst Joanne Wuensch upgraded Haemonetics (HAE) from a 'Neutral' to a 'Buy' rating and significantly raised the price target from $92 to $123. This upgrade indicates a …
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 65
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $125
Raymond James analyst Andrew Cooper has updated their outlook on Haemonetics, maintaining an 'Outperform' rating and raising the price target from $105 to $125. This indicates a st…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Haemonetics, Raises Price Target to $119
Baird analyst David Rescott maintained an 'Outperform' rating on Haemonetics (HAE) and significantly raised the price target from $96 to $119. This action signals increased confide…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 60
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $118
Barrington Research, through analyst Michael Petusky, has maintained an 'Outperform' rating on Haemonetics (HAE) and raised its price target from $95 to $118. This action signals i…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
Haemonetics Shares Hit New 52-Week High: What's Happening?
Haemonetics (HAE) announced a non-exclusive supply agreement with CSL Plasma Inc., allowing CSL to adopt Haemonetics’ NexSys PCS devices and Persona PLUS technology across its U.S.…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Haemonetics, Raises Price Target to $110
BTIG analyst Marie Thibault maintained a 'Buy' rating on Haemonetics and raised the price target from $96 to $110. This action signals increased analyst optimism regarding Haemonet…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
Haemonetics shares are trading higher after the company announced it entered into a supply agreement with CSL Plasma.
This supply agreement is a significant positive catalyst for Haemonetics, as it secures a major customer and likely expands its market share in the plasma collection equipment sect…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Haemonetics, Raises Price Target to $96
BTIG analyst Marie Thibault maintained a 'Buy' rating on Haemonetics and raised the price target from $84 to $96. This action signals a positive outlook from a reputable financial …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Haemonetics Q1 Adj. EPS $1.14 Beats $1.08 Estimate, Sales $339.380M Beat $327.894M Estimate
This headline is a significant corporate catalyst for Haemonetics (HAE). Beating both EPS and sales estimates by a notable margin indicates strong underlying business fundamentals,…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90
Mizuho analyst Anthony Petrone has maintained an 'Outperform' rating on Haemonetics (HAE) and raised the price target from $85 to $90. This action signals continued confidence from…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.